Skip to main content
Journal cover image

Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer.

Publication ,  Journal Article
Sloan, FA; Yashkin, AP; Akushevich, I; Inman, BA
Published in: Urologic oncology
February 2020

Bladder cancer (BC) is highly prevalent and costly. This study documented cost and use of services for BC care and for other (non-BC) care received over a 15-year follow-up period by a cohort of Medicare beneficiaries diagnosed with BC in 1998.Data came from the Surveillance, Epidemiology and End Results Program linked to Medicare claims. Medicare claims provided data on diagnoses, services provided, and Medicare Parts A and B payments. Cost was actual Medicare payments to providers inflated to 2018 US$. Cost and utilization were BC-related if the claim contained a BC diagnosis code. Otherwise, costs were for "other care." For utilization, we grouped Part B-covered services into 6 mutually-exclusive categories. Utilization rates were ratios of the count of claims in a particular category during a follow-up year divided by the number of beneficiaries with BC surviving to year-end.Cumulatively over 15-years, for all stages combined, total BC-related cost per BC beneficiary was $42,011 (95% Confidence Interval (CI): $42,405-$43,417); other care cost was about twice this number. Cumulative total BC-related cost of 15-year BC survivors for all stages was $43,770 (CI: $39,068-$48,522), intensity of BC-related care was highest during the first year following BC diagnosis, falling substantially thereafter. After follow-up year 5, there were few statistically significant changes in BC-related utilization. Utilization of other care remained constant during follow-up or increased.Substantial costs were incurred for non-BC care. While increasing BC survivorship is an important objective, non-BC care would remain a burden to Medicare.

Duke Scholars

Published In

Urologic oncology

DOI

EISSN

1873-2496

ISSN

1078-1439

Publication Date

February 2020

Volume

38

Issue

2

Start / End Page

39.e11 / 39.e19

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • United States
  • Medicare
  • Male
  • Longitudinal Studies
  • Humans
  • Health Care Costs
  • Female
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sloan, F. A., Yashkin, A. P., Akushevich, I., & Inman, B. A. (2020). Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. Urologic Oncology, 38(2), 39.e11-39.e19. https://doi.org/10.1016/j.urolonc.2019.10.016
Sloan, Frank A., Arseniy P. Yashkin, Igor Akushevich, and Brant A. Inman. “Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer.Urologic Oncology 38, no. 2 (February 2020): 39.e11-39.e19. https://doi.org/10.1016/j.urolonc.2019.10.016.
Sloan FA, Yashkin AP, Akushevich I, Inman BA. Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. Urologic oncology. 2020 Feb;38(2):39.e11-39.e19.
Sloan, Frank A., et al. “Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer.Urologic Oncology, vol. 38, no. 2, Feb. 2020, pp. 39.e11-39.e19. Epmc, doi:10.1016/j.urolonc.2019.10.016.
Sloan FA, Yashkin AP, Akushevich I, Inman BA. Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. Urologic oncology. 2020 Feb;38(2):39.e11-39.e19.
Journal cover image

Published In

Urologic oncology

DOI

EISSN

1873-2496

ISSN

1078-1439

Publication Date

February 2020

Volume

38

Issue

2

Start / End Page

39.e11 / 39.e19

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • United States
  • Medicare
  • Male
  • Longitudinal Studies
  • Humans
  • Health Care Costs
  • Female
  • Aged, 80 and over